-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the end of the seventh batch, the various expectations of the eighth batch of collection came to the
01 Biological products (biosimilars)
01 Biological products (biosimilars)Biosimilars, also known as biosimilars, are biological drugs (including vaccines, blood and blood components, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins)
Biosimilars are therapeutic biological products
On February 18, 2021, the Drug Review Center of the State Food and Drug Administration issued the Technical Guidelines for similarity evaluation and indications of biosimilars, which is called the signal
Biologics production processes are more complex and cannot establish consistency evaluation standards like chemicals, so it has been difficult for biologics to be collected on a large scale
The biggest difficulty in the national collection of biological products is how to delineate reasonable grouping according to the structure and indications
02 Chemicals
02 ChemicalsAt present, there are more than 80 chemical drugs that meet the conditions for the next batch of national procurement, and when it comes to the real collection, it is expected that there will be far more than this number
However, there are a few points worth noting:
First, when it comes to the real collection, the number of varieties that meet the conditions is far more than eighty
First, when it comes to the real collection, the number of varieties that meet the conditions is far more than eighty
2
2
Third, many products through the consistency evaluation of the number of enterprises to calculate the caliber is different
03 Dental implants
There are always voices in the industry that dental implants are not medical insurance projects, all at their own expense, do not understand why collection? But state procurement is not just about reducing health care spending
"Golden-eyed silver tooth copper bone", if the implant is successfully collected, it is beneficial to the patient, and no one can get around it
Among them, dental implants have the best effect, one 10,000-30,000, the author in the Database of the State Food and Drug Administration to query the implant found that 26 pieces of information in domestic production, 209 pieces of information
70% of this part of the market is reflected in private hospitals or clinics, so the final price of this collection and the implementation of the collection are worth waiting to see
Many people in the industry have analyzed that at the end of the year, a large-scale king fried collection and collection also makes sense
.